EN
SINOVAC Donates 100,000 Doses of Hepatitis A Vaccines to Pakistan
November 9, 2022, Islamabad -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company donated 100,000 doses of the hepatitis A vaccine, Healive® to Pakistan, to help improve the local communities' health conditions during the country's post-disaster reconstruction.
This year, Pakistan suffered from the worst floods in the country's history, posing severe challenges to local people's lives. Residents at relief camps are vulnerable to disease transmission, and the outbreak of hepatitis A virus is highly likely, according to the Pakistani Federal Health Minister, Mr. Abdul Qadir Patel.
"Providing assistance to the flood-affected populations of Pakistan is the government's top priority. We are really grateful for the donation of 100,000 doses of the hepatitis A vaccine from SINOVAC for children and adults," said the minister during the handing over ceremony held in Islamabad on Wednesday.
As one of the flagship products of SINOVAC, Healive® is the first and only hepatitis A vaccine from China, which passed the assessment under the WHO Prequalification Procedure. It offers sustained protection for over 30 years after full-course immunization. Including in Pakistan, Healive® has been registered in 21 countries and organizations around the world, and authorized to be administered in 33 countries and areas, so far.
Dr. Muhammad Ahmed Kazi, the Director General of Pakistan Federal Directorate of Immunization, said, "I thank the whole SINOVAC team for the assistance provided and assure that it will be used in the best possible manner to benefit the children and adult populations of Pakistan. We are looking forward to a continued partnership."
Gao Qiang, Chief Operating Officer of SINOVAC, said, "Pakistan and China are close friends and all-weather strategic partners. As a leading provider of biopharmaceutical products in China, SINOVAC has established a good friendship and partnership with Pakistan for years. The donation shows not only our care to the country, but also demonstrates the social responsibilities we are taking on."
Prior to the announced donation of the hepatitis A vaccine, SINOVAC has provided approximately 100 million doses of CoronaVac®, its COVID-19 vaccine, to Pakistan since the outbreak of COVID-19.
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, poliomyelitis, etc.
The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
For more information, please see the Company's website at www.sinovac.com.
Contact:
Sinovac Biotech Ltd.
PR Team
pr@sinovac.com
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.